, slated to report its March quarter results (Q4FY21) on May 6, is expected to post nearly 60 per cent year-on-year growth in earnings before interest, tax, depreciation, and amortization (Ebitda) aided by healthy sales volume and low base effect. However, price hikes taken due to BS-VI transition and to off-set increase in input costs may not be enough to cushion Ebitda margin hit, say analysts. READ MORE
reported a higher-than-expected consolidated net profit at Rs 6,644 crore in the March quarter (Q4) of FY21, against a net loss of Rs 1,481 crore in the corresponding period last year. The company’s performance was best-ever across metrics such as revenue, Ebitda and net profit (excluding exceptional items).
: The Cabinet Committee on Economic Affairs has given its in-principle approval for strategic disinvestment along with transfer of management control in IDBI Bank
Ltd, government said on Wednesday.
Adani Enterprises on Wednesday reported 282.2 per cent rise in consolidated net profit at Rs 233.95 crore for the quarter ended March 31, 2021. The consolidated income of the company during the quarter was at Rs 13,688.95 crore.
Tata Motors: The Competition Commission of India (CCI) has ordered a detailed probe against Tata Motors for alleged abuse of its dominant position with respect to dealership agreements.
Maruti Suzuki India, on Wednesday, said its total production in April 2021 stood at 159,955 units, down 7 per cent from March this year.
Maharashtra Seamless: ONGC has issued the letter of award to Jindal Drilling & Industries for deployment of Jack-up drilling rig 'Jindal Explorer' owned by Maharashtra Seamless on charter hire contract for a period of 3 years.
Praj Industries: HDFC Mutual Fund sold 434,583 equity shares (0.24 per cent) in Praj Industries via open market transaction on May 3, reducing shareholding to 6.51 per cent.
Adani Green Energy reported consolidated profit of Rs 104 crore for Q4FY21 against Rs 56 crore reported in Q4FY20.
Wipro partnered with Transcell Oncologics to transform vaccine safety assessment using augmented intelligence.
Cipla: Roche India, on May 5, said it received Emergency Use Authorisation (EUA) from the Central Drugs Standards Control Organisation (CDSCO) for the antibody cocktail Casirivimab and Imdevimab in India. Cipla will market and distribute the product in India.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.